ACON Stock Overview
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Aclarion, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.33 |
52 Week High | US$37.92 |
52 Week Low | US$0.27 |
Beta | 0 |
1 Month Change | -8.75% |
3 Month Change | -90.76% |
1 Year Change | -97.21% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.25% |
Recent News & Updates
Recent updates
Shareholder Returns
ACON | US Healthcare Services | US Market | |
---|---|---|---|
7D | -11.0% | 0.04% | 0.4% |
1Y | -97.2% | 5.7% | 28.8% |
Return vs Industry: ACON underperformed the US Healthcare Services industry which returned 5.8% over the past year.
Return vs Market: ACON underperformed the US Market which returned 29.5% over the past year.
Price Volatility
ACON volatility | |
---|---|
ACON Average Weekly Movement | 28.5% |
Healthcare Services Industry Average Movement | 10.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ACON's share price has been volatile over the past 3 months.
Volatility Over Time: ACON's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 5 | Brent Ness | https://www.aclarion.com |
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
Aclarion, Inc. Fundamentals Summary
ACON fundamental statistics | |
---|---|
Market cap | US$2.33m |
Earnings (TTM) | -US$4.91m |
Revenue (TTM) | US$75.40k |
30.9x
P/S Ratio-0.5x
P/E RatioIs ACON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACON income statement (TTM) | |
---|---|
Revenue | US$75.40k |
Cost of Revenue | US$75.73k |
Gross Profit | -US$324.00 |
Other Expenses | US$4.91m |
Earnings | -US$4.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.69 |
Gross Margin | -0.43% |
Net Profit Margin | -6,513.41% |
Debt/Equity Ratio | -154.6% |
How did ACON perform over the long term?
See historical performance and comparison